Amphion Innovations

• 18/04/13

  Director/PDMR Shareholding

• 17/04/13

  Trading Statement

• 28/03/13

  Change of Adviser

• 19/12/12

  Holding(s) in Company

• 13/12/12

  Fundraising

• 

  03/06/13

  Amphion Innovations' FireStar: Getting US medical databases on the same page

  Transferring patient records to electronic format and making those records "system agnostic" is a key to improving cost efficiency in the notoriously non-cost effect US healthcare system. Amphion Innovations portfolio company FireStar Software is addressing this need, which could result in US government savings of US$80bn a year.

• 

  17/04/13

  Amphion Innovations looking to licensing settlements to lift NAV

• 

  13/12/12

  Amphion Innovations raises funds

• 

  05/12/12

  Amphion company Motif agrees drug development deal with Indian group

• 

  02/10/12

  Amphion Innovations keeps faith in patents as pace of litigation quickens

  Amphion Innovations' chief executive Richard Morgan compares the firm's current legal programme to "fighting a war". For it is deeply involved in the arena of patent litigation, where every victory, however small, represents potentially huge gains.

   

• 

  19/09/12

  Amphion looking at financing options amid challenging market conditions

• 

  29/08/12

  Amphion Innovations updates on IP patent litigation

• 

  20/07/12

  UPDATE: Amphion Innovations expects net asset value increase in half year

• 

  20/07/12

  Amphion Innovations expects net asset value increase in half year

• 

  06/07/12

  Company Q&A: Amphion Innovations

  Here we speak with Amphion chief Richard Morgan about emerging technology and funding early stage companies.

• 

  18/03/2010

  Amphion Innovations One2One Investor Presentation 18 March 10 (PDF)

  Amphion Innovations One2One Investor Presentation 18 March 10

• 

  18/04/13

  Footsie closes down slightly as US equities fall
• 

  17/04/13

  Market Movers: Magnolia Petroleum, Afferro Mining, International Mining, Amphion Innovations, Petra Diamonds
• 

  12/03/13

  FTSE 100 closes up slighlty; miners in focus
• 

  20/12/12

  FTSE100 ends session slightly down; Amur Minerals shines in small caps
• 

  20/12/12

  FTSE 100 slips in afternoon trade; AMUR Minerals star of small caps

• 18/08/08

  18.08.08 :-0.5, (19.75) Charles Stanley has initiated coverage on Amphion Innovations with a ?hold? rating and 24 pence price target. In... read more

  18.08.08 :-0.5, (19.75) Charles Stanley has initiated coverage on Amphion Innovations with a ?hold? rating and 24 pence price target. In a note, the broker said its coverage reflects shorter-term market conditions. However, it notes positives such as the group?s three fundraisings since the first-half and its DataTern unit producing its first cash return to Amphion, which it thinks now holds the promise of substantial future licensing fees. Charles Stanley notes that the completed fundraisings led to the group?s net asset value rising 19 percent over the period. But it estimates that, DataTern aside, the running costs of Amphion tend to result in an operating loss of around $3 million per annum, which is reflected in its forecasts. It thinks further substantial licensing deals would position the business as self-financing, allowing for greater investment in partner companies, additional partner company investment or share buybacks, all of which would be positive for the share price.
• 13/03/08

  +0.50 +22.00

  higher in early deals, as it posted a 50% rise in full-year pretax profit, prompting a reiterated ?buy? rating from Charles Stanley.... read more

  higher in early deals, as it posted a 50% rise in full-year pretax profit, prompting a reiterated ?buy? rating from Charles Stanley. Earlier today, the developer of medical and technology businesses said pretax profit for the year to Dec 31 2007 rose 50% to 10.6m usd from 7m in the year-ago period. Its net asset value also rose, reflecting an increase in the value of its investments, although it warned it may not be able to sustain NAV growth at high levels in the long term. Reacting, Charles Stanley kept a ?buy? on the stock, saying although the financing market is clearly likely to remain tough in 2008, it thinks a 25% growth in value for Amphion seems eminently achievable. It bases this view on the number of funding rounds in the pipeline and the secular growth opportunities afforded by many of Amphion?s target markets. It told buyers to then hold the stock, as it noted management?s prediction of a significant liquidity event during 2008, possibly an Initial public offering or a trade sale.

The Company’s Business and Methodology

Amphion’s business is the formation, development, operation and financing of market-leading life science and technology companies in partnership with corporations, governments, universities and entrepreneurs seeking to commercialize their intellectual property. Building upon two decades of disciplined investment and operating expertise, the building of numerous successful public and private companies, and over $20 billion in value creation, Amphion provides an opportunity to participate in both public and private early-stage investments, with a primary focus on life science and technology companies 

Amphion’s Value-Creation Process

The Directors believe that the key to Amphion’s success will be the continued pursuit of the management’s successful multi-phase process for value creation.

Through its experience in building more than 30 companies, the Management Team has developed a process which generally can be broken down into distinct phases. Set out below is a representation of Amphion’s value-creation process, showing the five key phases described in more detail.

Value-Creation Process

Phase I. Creation and sourcing of opportunities

Working with universities, corporations, governments and entrepreneurs seeking to commercialize their intellectual property, Amphion identifies potential company-building opportunities. Throughout the process, Amphion maximizes value creation by drawing upon a collaborative network of strategic partners built over 20 years. This network provides access to innovative technologies, enhances its ability to identify and address unmet market needs and solicits the guidance of industry and technical experts. While this network is a key source of opportunities, it also provides advice and counsel throughout the company-building process that may be technical, financial or business-related and ultimately helps the Partner Companies compete and grow.

Phase II. Down-selection of opportunities

Amphion devotes considerable time and resources to screening for the most attractive business models and proven technology platforms from the available opportunities. Potential opportunities must also provide a tractable corporate and ownership position to ensure that Amphion will be able to implement its company-building process.

Central to Amphion’s selection and investment strategy is rigorous risk management based on identifying companies with proven technology and a quantifiable, verifiable business opportunity. Amphion does not invest in “speculative” technologies requiring long development timeframes or excessive capital investment; it looks for defensible core intellectual property and know-how for long-term competitive advantage, and growth potential in very large markets of at least $1 billion in size — and actively works with Partner Companies from the earliest stages to identify and defend core intellectual property (‘IP’).

For an example of our selection process, please click here

Phase III. Adaptive strategic positioning

Amphion then seeks to optimize its Partner Companies’ products and market positioning through refining or changing the emerging company’s market focus, business model, or strengthening the company management. Concurrently with this process, Amphion will undertake a review of the intellectual property, both strategic IP (i.e. what can be protected) and tactical IP (i.e. what can be protected) both to defend and expand the Partner Company’s competitive advantage and lead time over competitors.

Optimizing the business is often a “trial and error” process of rapid iteration and learning, with the objective of creating a company targeted on the greatest commercial opportunity that also provides a sustainable source of competitive advantage.

From this stage on, Amphion accelerates company development through a methodical and focused application of financial and human resources. The Management Team has traditionally adopted a hands-on approach with each new investment, seconding existing Amphion management to new Partner Companies in order to utilize Amphion’s accumulated knowledge in the company value-creation process, while gaining additional experience and insight which can be applied to subsequent investments.

Phase IV. Scaling and execution

In building its Partner Companies, Amphion typically provides a wide range of services including direct management, strategic planning, intellectual property planning and strategy, capital raising from Amphion’s network of investors, recruiting, business development, and other advisory services in areas such as marketing, administration, and capital markets. Amphion provides these services under an advisory agreement with the partner company and receives fees for doing so.

Amphion will then identify and recruit leading industry talent from its network of life science and technology partners and contacts to strengthen the management of the Partner Company, leading it to the next stage of development, generally an initial public offering or trade sale.

Phase V. Expansion and development

With an experienced industry team in place, Amphion continues to work with its companies over the long term, staying integrally involved with management, and seeking to influence and manage the boards and advisory committees to build value for both Amphion and Partner Company shareholders. To assist in this, Amphion will typically maintain a sizable ownership stake and measure of influence or control in the relevant Partner Company.

Throughout the company-building process, the Management Team strives to ensure that investor interests come before its own, and that the Company’s commitment to its Partner Companies, and investors, is a long-term one. The Company’s philosophy is to support its Partner Companies through difficult times, and provide additional management support when necessary to help them successfully weather downturns while improving their positioning for subsequent upturns.

Current Portfolio Summary (as it December 2011)

Company	Amphion Holding	Company Description
	14.75%	RFID systems for a range of applications
	14.38%	Software platform for inter-enterprise integration
	14.82%	Digital x-ray systems  for medical and security applications
	25.88%	MRI coils & tools for clinical  and research use
	33.49%	Population genetics for  pharmaceuticals and diagnostics
	22.61%	Online energy trading marketplace
	15.30%	Nutrigenomics for health & wellness

Specialized Entity

Company	Amphion Holding	Company Description
	100%	Intellectual Property Development

* As DataTern is 100% owned by Amphion, it is consolidated into Amphion’s financial statements.

Robert J. Bertoldi, Executive Director

Anthony W. Henfrey, Non-executive Director

R. James Macaleer, Non-executive Chairman

Richard C. E. Morgan, Executive Director

Gerard M. Moufflet, Non-executive Director

Jerel Whittingham, Executive Director

Click here for information on Amphion's Management Team

Click here for investor information